CoChat

Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL

Open access
Susilo, Monica E., Li, Chi‐Chung, Gadkar, Kapil, Hernandez, Genevive, Huw, Ling‐Yuh, Jin, Jin Y., Yin, Shen, Wei, Michael C., Ramanujan, Saroja, Hosseini, Iraj · 2023 · Clinical and Translational Science
Cited by 78

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Phase I oncology clinical trials often comprise a limited number of patients representing different disease subtypes who are divided into cohorts receiving treatment(s) at different dosing levels and schedules. Here, we leverage a previously developed quantitative systems pharmacology model of the anti‐CD20/CD3 T‐cell engaging bispecific antibody, mosunetuzumab, to account for different dosing regimens and patient heterogeneity in the phase I study to inform clinical dose/exposure‐response relationships and to identify biological determinants of clinical response. We developed a novel workflow to generate digital twins for each patient, which together form a virtual population (VPOP) that represented variability in biological, pharmacological, and tumor‐related parameters from the phase I trial. Simulations based on the VPOP predict that an increase in mosunetuzumab exposure increases the proportion of digital twins with at least a 50% reduction in tumor size by day 42. Simulations also predict a left‐shift of the exposure‐response in patients diagnosed with indolent compared to aggressive non‐Hodgkin's lymphoma (NHL) subtype; this increased sensitivity in indolent NHL was attributed to the lower inferred values of tumor proliferation rate and baseline T‐cell infiltration in the corresponding digital twins. Notably, the inferred digital twin parameters from clinical responders and nonresponders show that the potential biological difference that can influence response include tumor parameters (tumor size, proliferation rate, and baseline T‐cell infiltration) and parameters defining the effect of mosunetuzumab on T‐cell activation and B‐cell killing. Finally, the model simulations suggest intratumor expansion of pre‐existing T‐cells, rather than an influx of systemically expanded T‐cells, underlies the antitumor activity of mosunetuzumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cts.13501

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 78

Metadata

Authors
Susilo, M. E., Li, C., Gadkar, K., Hernandez, G., Huw, L., Jin, J. Y., Yin, S., Wei, M. C., Ramanujan, S., & Hosseini, I.
Venue
Clinical and Translational Science
Publisher
Wiley
Published
2023-03-23
Volume
16
Issue
7
Pages
1134-1148
ISSN
  • 1752-8054 (ISSN-L)
  • 1752-8062
OpenAlex
W4324017666
Cited by
78
References
3
FWCI
15.39
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. https://app.cochat.ai/papers/10.1111/cts.13501
The paper
Susilo, M. E., Li, C., Gadkar, K., Hernandez, G., Huw, L., Jin, J. Y., Yin, S., Wei, M. C., Ramanujan, S., & Hosseini, I. (2023). Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clinical and Translational Science. https://doi.org/10.1111/cts.13501

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.